Question 1

Why is the basement membrane tube assay considered weak evidence?

Accepted Answer

Endothelial cells rearrange into network patterns on that substrate within hours through migration and alignment, without proliferation or lumen formation, and they do so under almost any condition. It is useful as a rapid screen but cannot support a claim about angiogenesis. Sprouting from spheroids or beads, or organotypic co-culture, gives far stronger evidence.

Question 2

Which quantitative measures should sprouting assays report?

Accepted Answer

Sprout number per spheroid, cumulative sprout length, branch point count and, where resolvable, lumen presence. Analysis should be automated or blinded, since manual tracing of these structures is prone to expectation effects. Reporting the number of spheroids and independent experiments matters as much as the measures themselves.

Question 3

How is perfusion distinguished from vessel density?

Accepted Answer

Immunostaining counts structures that may be collapsed, disconnected or unperfused. Injecting a tracer before sacrifice labels only vessels carrying flow, and contrast imaging or oxygen measurement report tissue-level delivery directly. In ischaemia work especially, functional recovery depends on perfusion, so density alone can support a conclusion the tissue does not.

Question 4

What does vessel normalisation mean in the oncology setting?

Accepted Answer

Tumour vessels are tortuous, leaky and poorly covered by pericytes, which raises interstitial pressure and impairs delivery. Moderate anti-angiogenic dosing can restore a more regular structure and improve perfusion transiently rather than reducing vessel number. Demonstrating it requires measuring vessel morphology, pericyte coverage and drug or immune cell delivery together within a defined window.

Question 5

Why is dose-response often non-monotonic?

Accepted Answer

High local concentrations of growth factor produce leaky, disorganised vessels that regress once delivery stops, while moderate sustained levels support stable vasculature. The same applies inversely to inhibition, where excessive dosing prunes vessels and worsens delivery. Testing a concentration series is therefore essential rather than optional in both directions.

Question 6

How is vessel persistence assessed?

Accepted Answer

New vessels lacking mural cell coverage regress within weeks of treatment withdrawal. Following animals well past the dosing period, with pericyte and smooth muscle staining alongside perfusion measurement at each timepoint, distinguishes durable vasculature from a transient response that endpoint-only studies would report as success.

Biotechnology

Biotechnology

Research Frontiers in Angiogenesis Stimulation and Inhibition